The Impact of the COVID-19 Pandemic on Patient Disparities in Long-Term Opioid Therapy

J Am Board Fam Med. 2024 Mar-Apr;37(2):290-294. doi: 10.3122/jabfm.2023.230359R1.

Abstract

Background: The COVID-19 pandemic disrupted how primary care patients with chronic pain received care. Our study sought to understand how long-term opioid therapy (LtOT) for chronic pain changed over the course of the pandemic overall and for different demographic subgroups.

Methods: We used data from electronic health records of 64 primary care clinics across Washington state and Idaho to identify patients who had a chronic pain diagnosis and were receiving long-term opioid therapy. We defined 10-month periods in 2019 to 2021 as prepandemic, early pandemic and late pandemic and used generalized estimating equations analysis to compare across these time periods and demographic characteristics.

Results: We found a proportional decrease in LtOT for chronic pain in the early months of the pandemic (OR = 0.94, P = .007) followed by an increase late pandemic (OR = 1.08, P = .002). Comparing late pandemic to prepandemic, identifying as Asian or Black, having fewer comorbidities, or living in an urban area were associated with higher likelihood of being prescribed LtOT.

Discussion: The use of LtOT for chronic pain in primary care has increased from before to after the COVID-19 pandemic with racial/ethnic and geographic disparities. Future research is needed to understand these disparities in LtOT and their effect on patient outcomes.

Keywords: COVID-19; Chronic Pain; Healthcare Disparities; Idaho; Opioids; Pandemics; Primary Health Care; Substance Use Disorders; Washington.

MeSH terms

  • Adult
  • Aged
  • Analgesics, Opioid* / therapeutic use
  • COVID-19* / epidemiology
  • Chronic Pain* / drug therapy
  • Chronic Pain* / epidemiology
  • Female
  • Healthcare Disparities* / statistics & numerical data
  • Humans
  • Idaho / epidemiology
  • Male
  • Middle Aged
  • Pandemics
  • Primary Health Care* / statistics & numerical data
  • SARS-CoV-2
  • Washington / epidemiology

Substances

  • Analgesics, Opioid